All articles tagged with #bone mineral density
A debate has emerged over whether bone mineral density (BMD) targets should guide osteoporosis treatment. While some task forces advocate for goal-directed therapy, critics argue that BMD changes do not reliably predict fracture reduction, suggesting that clinical decisions should prioritize individual risk factors and fracture history over specific density numbers.
A Flinders University study of 9,704 women aged 65+ over 10 years found tea consumption was associated with higher hip bone mineral density, while drinking more than five cups of coffee daily correlated with lower bone density in older postmenopausal women; moderate coffee (2–3 cups/day) showed no negative effect. Effects varied with obesity and alcohol use, suggesting tea may support bone health and that very high coffee intake should be moderated, alongside calcium, vitamin D and weight-bearing exercise to prevent osteoporosis.
A comprehensive umbrella review of 92 syntheses including 1,744 randomized trials finds traditional Chinese exercises (tai chi, qigong, baduanjin, wuqinxi, yijinjing) provide high-certainty improvements in pain, function, mental health, sleep, and bone density for people with musculoskeletal conditions; tai chi shows notable benefits in knee osteoarthritis and osteoporosis, with the strongest effects after long-term, regular practice (≥150 minutes/week, ≥3 sessions/week for >6 months).
A study of about 9,700 US women over 65 found regular tea drinkers had modestly higher hip bone mineral density, possibly due to tea catechins, while higher coffee intake (>5 cups/day) correlated with lower bone density, especially among lifetime alcohol consumers; results suggest tea may support bone health but do not recommend increasing coffee, and calcium/vitamin D remain key to bone health.
Amgen's stock rebounded after concerns about its weight-loss drug MariTide causing bone mineral density loss were deemed "overdone" by analysts. Despite a 7% stock drop due to initial fears, experts argue that significant weight loss often correlates with reduced bone density. Amgen maintains confidence in MariTide, with Phase 2 trial results expected later this year. Analysts note that while rival drugs from Eli Lilly and Viking Therapeutics may offer bone health benefits, the impact of MariTide remains uncertain pending further data.
Amgen's stock fell 7% after reports suggested its weight-loss drug, MariTide, may be linked to bone mineral density loss. Analyst Olivia Brayer maintained an overweight rating but highlighted concerns over a dose-dependent increase in bone density loss. This poses a significant risk for Amgen, as MariTide competes with similar drugs from Novo Nordisk and Eli Lilly. The potential side effect could affect the drug's commercial viability, especially as competitors' drugs may increase bone density.
Amgen's shares declined after Cantor Fitzgerald raised safety concerns about its obesity drug candidate, MariTide (AMG-133), citing potential risks of bone mineral density loss.
A large-scale study in Korea found that postmenopausal women with osteoporosis, characterized by low bone mineral density (BMD), have an increased risk of developing Parkinson's disease. The study included over 270,000 women and revealed that individuals with osteoporosis had a 40% higher risk of Parkinson's compared to those with normal BMD. However, the use of medications to treat osteoporosis significantly reduced this elevated risk. The findings suggest that proper management of BMD in postmenopausal women may help prevent Parkinson's disease.